. 2019 Oct 22;17:347. doi: 10.1186/s12967-019-2093-y

Table 1.

Clinicopathological characteristics of eligible studies

Study [Ref.]	Country	miRNA-130a		miRNA-130b		Histology	TNM stage	Sample	Assay	Follow-up (months)	Cut-off	HR (95% CI)
Study [Ref.]	Country	OS	Other	OS	Other	Histology	TNM stage	Sample	Assay	Follow-up (months)	Cut-off	OS	DFS/PFS
Jia 2019 [44]	China	284				Gastric cancer	I–IV	Frozen tissue	qRT-PCR	50	Median	2.44 (1.35,4.40)
Peng 2018 [18]	China	333	DFS,333			Gastric cancer	I–III	Serum	qRT-PCR	59	Median	1.49 (0.99,2.26)	1.38 (0.99,1.91)
Liu 2018 [45]	China	369				Colorectal cancer	I–IV	Serum	qRT-PCR	60	Median	2.36 (1.07,5.22)
Yang 2018 [46]	China	60	DFS,60			Colorectal cancer	I–IV	Frozen tissue	qRT-PCR	70	Median	2.25 (1.05,4.83)
Asukai 2017 [16]	Japan	27	DFS,27			Cholangiocarcinoma	NA	Frozen tissue	qRT-PCR	82	Median	2.36 (1.18,4.17)	2.47 (1.10,5.56)
Zhou 2017 [47]	China	51				HCC	I–III	Frozen tissue	qRT-PCR	42	Normal	1.23 (0.78,1.96)
Chen 2016 [11]	China	86	DFS,86			Osteosarcoma	I–IV	Frozen tissue	qRT-PCR	60	Median	2.14 (1.14,4.02)	2.04 (1.22,3.40)
Jiang 2016 [17]	China	41				Gastric cancer	I–III	Frozen tissue	qRT-PCR	36	Normal	2.05 (1.03,4.08)
Yuan 2016 [14]	China	56				Lymphoma	NA	Frozen tissue	qRT-PCR	50	Median	1.23 (0.94,1.61)
He 2014 [15]	China	73	DFS,73			Cervical cancer	I–IV	Frozen tissue	qRT-PCR	86	Normal	1.41 (0.30,6.63)	1.73 (0.14,21.52)
Li 2014 [21]	China	102				HCC	I–III	Frozen tissue	qRT-PCR	72	Normal	0.45 (0.22,0.90)
Wang 2012 [48]	China		DFS,100			NSCLC	I–III	Frozen tissue	qRT-PCR	96	Normal		0.21 (0.09,0.50)
Hashimoto 2019 [49]	America (AA)			36		Prostate cancer	I–IV	Frozen tissue	qRT-PCR	260	Mean	22.4 (2.27,221.3)
Hashimoto 2019 [49]	America (EA)			57		Prostate cancer	I–IV	Frozen tissue	qRT-PCR	250	Mean	1.10 (0.21,5.74)
Ulivi 2019 [50]	Italy			83	DFS,85	NSCLC	I–IIIA	Serum	qRT-PCR	160	Median	1.35 (1.08,1.69)	1.35 (1.08,1.69)
Hu 2018 [51]	China			110		HCC	NA	Serum	qRT-PCR	60	Median	6.58 (3.04,14.24)
Ecke 2017 [52]	Germany (TC)			100		Bladder-cancer	NA	Frozen tissue	qRT-PCR	156	Median	0.99 (0.82,1.20)
Ecke 2017 [52]	Germany (VC)			56		Bladder-cancer	NA	Frozen tissue	qRT-PCR	156	Median	1.02 (0.53,1.96)
Li 2017 [22]	China			85		Glioma	NA	Frozen tissue	qRT-PCR	36	Mean	2.22(1.38,3.56)
Chang 2016 [23]	China (TC)			85	DFS,85	HCC	I–III	Frozen tissue	qRT-PCR	66	Normal	1.01 (0.38,2.72)	2.02 (1.33,3.07)
Chang 2016 [23]	China (VC)			65	DFS,65	HCC	I–III	Frozen tissue	qRT-PCR	80	Normal	1.93 (1.30,2.87)	1.73 (1.16,2.58)
Sheng 2015 [24]	China			86		Glioma	NA	Frozen tissue	qRT-PCR	36	Median	4.39 (1.50,12.82)
Wang 2014 [25]	China			97	DFS,97	HCC	I–IV	Frozen tissue	qRT-PCR	60	Median	2.52 (1.24,5.15)	4.00 (1.52,10.54)
Kjersem 2014 [30]	Norway			150	PFS,150	Colorectal cancer	NA	Serum	qRT-PCR	NA	Median	1.31 (0.96,1.79)	1.40 (1.05,1.86)
Colangelo 2013 [26]	Italy			80		Colorectal Cancer	I–IV	Frozen tissue	qRT-PCR	108	Mean	5.99 (1.99,18.03)
Zhao 2013 [31]	China			52		Pancreatic cancer	I–IV	Frozen tissue	qRT-PCR	36	Median	2.84 (1.25,6.45)
Nakatani 2012 [53]	Italy			49		Sarcoma	NA	Frozen tissue	qRT-PCR	217	Median	2.11 (1.22,3.63)

NSCLC, non-small cell lung cancer; HCC, hepatocellular cancer; qRT-PCR, quantitative real-time PCR; OS, overall survival; PFS, progressive free survival; DFS, disease free survival; SC, survival curve; AA, African-American; EA, European-American; TC,Training cohort; VC, Validation cohort